Showing results (311-320 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|January 1, 1995
Conjugation of carcinogens by theta class glutathione s-transferases: mechanisms and relevance to variations in human riskF P Guengerich, R Thier, M Persmark, et al.Pharmacogenetics|January 1, 1995
Metabolic polymorphisms and carcinogen-DNA adduct formation in human populationsK R Kaderlik, F F KadlubarPharmacogenetics|January 1, 1995
Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver diseaseS Kato, M Onda, N Matsukura, et al.Pharmacogenetics|January 1, 1995
CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, BrazilH Sugimura, G S Hamada, I Suzuki, et al.Pharmacogenetics|January 1, 1995
Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humansH Bartsch, M Rojas, K Alexandrov, et al.Pharmacogenetics|October 1, 1996
A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotypeT Yokoi, Y Kosaka, M Chida, et al.Pharmacogenetics|October 1, 1996
Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoproteinF Hervé, J C Duché, P d'Athis, et al.Pharmacogenetics|October 1, 1996
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reactionT Stüven, E U Griese, H K Kroemer, et al.Pharmacogenetics|October 1, 1996
Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white populationJ A Agúndez, M Olivera, C Martínez, et al.Pharmacogenetics|October 1, 1996
Genetic analysis of the human cytochrome P450 CYP2C9 locusM J Stubbins, L W Harries, G Smith, et al.Pageof 83